Clinical Trials | October 16, 2025
Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies
These findings follow positive Phase 3 results presented earlier this year
These findings follow positive Phase 3 results presented earlier this year
Merck will showcase results in innovative solutions in HIV treatment and prevention
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
